Kit and method for enriching, concentrating and / or detecting PCOS-related steroid hormones
Through the combination of amphiphilic magnetic solid phase materials and liquid chromatography tandem mass spectrometry, the sensitivity and accuracy problems in PCOS-related steroid hormone detection are solved, and the simultaneous detection and efficient separation of multiple hormones are achieved, reducing costs and matrix interference.
Patent Information
- Application Number
- CN202411074804.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-07
AI Technical Summary
The prior art has problems such as low sensitivity, inaccurate quantification, severe interference of structural analogs, long detection time and high cost when detecting polycystic ovary syndrome (PCOS), and it is impossible to detect multiple hormones at the same time.
SiO2@Fe3O4 magnetic particles were prepared by pyrolysis treatment by pyrolysis, combined with liquid chromatography tandem mass spectrometry, the mobile phase and elution procedures were optimized, and sample pretreatment and detection were used with low concentration acid solution.
High specific separation of a variety of PCOS-related steroid hormones is achieved, which reduces matrix interference, improves detection accuracy and efficiency, simplifies operational processes, and reduces costs.
Smart Images

Figure CN118604217B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of analysis and detection, and in particular to a kit and method for enriching, concentrating and / or detecting PCOS-related steroid hormones. Background Art
[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.
[0003] Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects approximately 1 in 15 women of childbearing age. Its symptoms vary, mainly including androgen excess (hirsutism and acne), menstrual irregularities, and metabolic dysfunction (obesity, insulin resistance, acanthosis nigricans). PCOS is also one of the most common causes of female infertility. It is estimated that 75% of PCOS patients remain undiagnosed, mainly due to the diversity of symptoms and inconsistent clinical diagnostic criteria. More than one-third of women with PCOS spend at least 2 years and consult at least three medical professionals before the disease is diagnosed. There is no single standard or test method for diagnosing PCOS, which is mainly based on excluding diseases with similar symptoms. The most commonly used method for diagnosing PCOS is to define PCOS based on at least 2 of the 3 criteria: (1) androgen excess; (2) ovulatory dysfunction; and (3) polycystic ovary morphology (PCOM). Many steroid hormone endocrine diseases (such as those diagnosed with Cushing's syndrome, nonclassical CAH, virilizing tumors, and hyperandrogenemia) also meet the criteria for diagnosing PCOS. Therefore, PCOS should be diagnosed only after other medical conditions have been ruled out.
[0004] Steroid hormones mainly exist in the form of protein binding, and human blood contains a lot of high-affinity binding proteins, with complex composition, large differences in the content of different hormones, and many structural analogs and isomers, which are easy to interfere with each other. To achieve accurate quantification, high requirements are placed on sensitivity and accuracy. It is necessary to select a suitable sample pretreatment method to enrich the target, improve sensitivity, and eliminate or reduce matrix interference. At present, immunoassays are mostly used in China to determine steroid hormones in blood. A large number of literatures have confirmed that immunoassays are often interfered by structural analogs and substrates when determining steroid hormones, resulting in inaccurate measurement results, high quantitative limits, and narrow linear ranges. At the same time, each immunoassay can only measure one steroid hormone, and the detection time is long. This brings many obstacles to the exclusion diagnosis of PCOS, so there is an urgent need for simple, easy, economical, high-throughput and accurate quantitative detection methods.
[0005] Currently, tandem mass spectrometry is used to determine a variety of steroid hormones. Generally, the following sample pretreatment methods are used for blood sample processing: first, the sample is subjected to liquid-liquid extraction after protein precipitation. The solvent for liquid-liquid extraction is generally volatile organic reagents such as ethyl acetate, n-hexane, and methyl tert-butyl ether. Leakage is very likely to occur during the removal of the supernatant, resulting in sample loss or contamination, and high requirements are placed on personnel; second, the sample is derivatized after protein precipitation and then subjected to liquid-liquid extraction. Although this can improve the sensitivity of the analyte, the operation is cumbersome, and many analytes have double peaks that cannot be baseline-separated after derivatization, resulting in inaccurate quantitative integration results; third, the sample is subjected to solid phase extraction after protein precipitation. There are many operating steps, and consumables such as solid phase extraction columns are relatively expensive, which increases the detection cost.
[0006] In view of this, the present invention is proposed. Summary of the invention
[0007] The object of the present invention is to provide an amphiphilic magnetic solid phase material and the use of the amphiphilic magnetic solid phase material in enriching, concentrating and / or detecting PCOS-related steroid hormones, so as to alleviate the defects in steroid hormone detection in the prior art.
[0008] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:
[0009] In a first aspect, a kit for enriching, concentrating and / or detecting PCOS-related steroid hormones is provided, the kit comprising an amphiphilic magnetic solid phase material, an activation solution, a balancing solution, a dissociation solution, a first eluent, a second eluent and an elution solution;
[0010] The amphiphilic magnetic solid phase material is a magnetic particle SiO2@Fe3O4 mixed with humic acid and then pyrolyzed at 300-900°C for 0.5-1.5 h to obtain a magnetic particle with a carbonaceous phase on the surface; the magnetic particle SiO2@Fe3O4 is a nanoparticle with a core-shell structure in which SiO2 encapsulates Fe3O4;
[0011] The activation solution includes methanol;
[0012] The equilibrium solution comprises an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-10%, and the proportion of methanol is not 0;
[0013] The dissociation solution includes an ammonium acetate-acetic acid buffer solution with a pH range of 5 to 6;
[0014] The first eluent comprises an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-30%, and the proportion of methanol is not 0;
[0015] The second eluent comprises one or more of n-hexane, isohexane and cyclohexane;
[0016] The eluent includes one or more of methanol, acetonitrile and isopropanol solution;
[0017] The PCOS-related steroid hormones include one or more of progesterone, 17α-hydroxyprogesterone, 11-deoxycorticosterone, aldosterone, 11-deoxycortisol, cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstenedione, testosterone, 17α-hydroxypregnenolone, pregnenolone and dihydrotestosterone.
[0018] In a second aspect, a sample pre-treatment method is also provided, comprising using the amphiphilic magnetic solid phase material of the first aspect, or the kit of the first aspect to enrich and / or concentrate the PCOS-related steroid hormones in the sample;
[0019] The sample pretreatment method comprises mixing the amphiphilic magnetic solid phase material that has been subjected to activation treatment and equilibrium treatment in sequence with a sample system, so that the amphiphilic magnetic solid phase material adsorbs PCOS-related steroid hormones in the sample, and then separating the amphiphilic magnetic solid phase material and mixing it with a first eluent, separating the amphiphilic magnetic solid phase material and then mixing it with a second eluent, eluting with an eluent and collecting the eluent, wherein the eluent contains the PCOS-related steroid hormones in the sample for subsequent detection;
[0020] The activation treatment comprises mixing an activation solution with the amphiphilic magnetic solid phase material;
[0021] The balancing treatment comprises mixing the activated amphiphilic magnetic solid phase material with a balancing solution;
[0022] The sample system includes a sample, methanol and a dissociation solution;
[0023] The activation solution, balancing solution, dissociation solution, first eluent, second eluent and elution solution are all the activation solution, balancing solution, dissociation solution, first eluent, second eluent and elution solution in the first aspect.
[0024] In a third aspect, a method for detecting PCOS-related steroid hormones is also provided, comprising enriching and / or concentrating the PCOS-related steroid hormones in the sample using the amphiphilic magnetic solid phase material of the first aspect, and then analyzing the PCOS-related steroid hormones in the sample using liquid chromatography tandem mass spectrometry;
[0025] Liquid chromatography conditions included:
[0026] The chromatographic column used is C18 chromatographic column;
[0027] The mobile phase system includes mobile phase A and mobile phase B;
[0028] The mobile phase A is an aqueous solution of ammonium formate or an aqueous solution of ammonium acetate, and the mobile phase A contains no more than 0.001% v / v formic acid; the mobile phase B is a methanol solution of ammonium formate or a methanol solution of ammonium acetate, and the mobile phase B contains no more than 0.001% v / v formic acid.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] The present invention enriches, concentrates and / or detects steroid hormones through an amphiphilic magnetic solid phase extraction material. The amphiphilic magnetic solid phase extraction material is an amphiphilic magnetic solid phase extraction material based on SiO2@Fe3O4 magnetic particles prepared by a one-pot method. The entire preparation process is simple, reproducible and environmentally friendly (no organic solvent or harmful chemical substances are involved). The preparation method uses low-cost, large-volume available starting raw materials (silicon dioxide and humic acid), and the obtained magnetic particles are of moderate size, basically in the range of 1 to 50 μm. The raw material humic acid used is a macromolecular base structure material composed of a hydrophobic framework and abundant hydrophilic groups, which can be converted into an aromatic carbonaceous phase containing oxygen-containing functional groups through a simple pyrolysis treatment, producing a new mixed mode carbonaceous phase group with good hydrophilicity and lipophilicity. The obtained magnetic particles have a good enrichment and separation effect on endogenous small molecule organic matter, greatly reducing the matrix effect in the steroid detection process, ensuring the accuracy of the quantitative method, and facilitating the simultaneous detection of multiple PCOS-related steroid hormones.
[0031] The present invention optimizes the magnetic particle extraction process and the detection method of liquid chromatography tandem mass spectrometry, especially optimizes the mobile phase and elution procedure, adopts an extremely low concentration acidic solution that is not conventionally used, and obtains a good separation effect. Ammonium fluoride, an ion pair reagent commonly used in steroid hormone liquid chromatography analysis, is not used. A series of problems caused by using ammonium fluoride as a mobile phase are avoided. For example, when using ammonium fluoride, the chromatographic column needs to be strictly mixed with a non-ammonium fluoride mobile phase. The analysis system that has used ammonium fluoride must use a non-acidic mobile phase to flush the pipeline to avoid corrosion to the pipeline. At the same time, long-term use will reduce the service life of the chromatographic column. The limitation of the mobile phase leads to a significant reduction in the use efficiency of the entire liquid-mass system, thereby increasing the use cost. The detection method of PCOS-related steroid hormones provided by the present invention can achieve high-specificity separation of a variety of PCOS-related steroid hormones in a relatively short period of time. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0033] Figure 1 The progesterone residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0034] Figure 2 It is the progesterone chromatogram of the detection method of Example 2;
[0035] Figure 3 The 17a-hydroxyprogesterone residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0036] Figure 4 17a-hydroxyprogesterone chromatogram of the detection method of Example 2;
[0037] Figure 5 The residual graph (upper) and linear curve graph (lower) of 11-deoxycorticosterone of the detection method of Example 2;
[0038] Figure 6 11-deoxycorticosterone chromatogram of the detection method of Example 2;
[0039] Figure 7 The aldosterone residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0040] Figure 8 is the aldosterone chromatogram of the detection method of Example 2;
[0041] Fig. 9 The residual graph (upper) and linear curve graph (lower) of 11-deoxycortisol of the detection method of Example 2;
[0042] Fig.10 11-deoxycortisol chromatogram of the detection method of Example 2;
[0043] Fig.11 The cortisol residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0044] Fig.12 The cortisol chromatogram of the detection method of Example 2;
[0045] Fig.13 The dehydroepiandrosterone residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0046] Fig.14 The dehydroepiandrosterone chromatogram of the detection method of Example 2;
[0047] Fig.15 The residual graph (upper) and linear curve graph (lower) of dehydroepiandrosterone sulfate of the detection method of Example 2;
[0048] Fig.16 The chromatogram of dehydroepiandrosterone sulfate of the detection method of Example 2;
[0049] Fig.17 The androstenedione residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0050] Fig.18 It is the androstenedione chromatogram of the detection method of Example 2;
[0051] Fig.19 The testosterone residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0052] Fig. 20 It is the testosterone chromatogram of the detection method of Example 2;
[0053] Fig.21 The residual graph (upper) and linear curve graph (lower) of pregnenolone of the detection method of Example 2;
[0054] Fig. 22 It is the pregnenolone chromatogram of the detection method of Example 2;
[0055] Fig.23 The residual graph (upper) and linear curve graph (lower) of 17-hydroxypregnenolone of the detection method of Example 2;
[0056] Fig.24 17-hydroxypregnenolone chromatogram of the detection method of Example 2;
[0057] Fig.25 The dihydrotestosterone residual graph (upper) and linear curve graph (lower) of the detection method of Example 2;
[0058] Fig.26 It is the dihydrotestosterone chromatogram of the detection method of Example 2;
[0059] Fig. 27 The dihydrotestosterone chromatogram of the mobile phase numbered 1 in Example 5 is shown;
[0060] Fig.28 This is the chromatogram of 17-hydroxypregnenolone-IS using the mobile phase No. 1 in Example 5;
[0061] Fig.29 The dihydrotestosterone chromatogram is the mobile phase using number 2 in Example 5;
[0062] Fig.30 This is the chromatogram of 17-hydroxypregnenolone-IS using the mobile phase No. 2 in Example 5;
[0063] Fig.31 The dihydrotestosterone chromatogram is the mobile phase using number 3 in Example 5;
[0064] Fig.32 This is the chromatogram of 17-hydroxypregnenolone-IS using mobile phase No. 3 in Example 5. DETAILED DESCRIPTION
[0065] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0066] In a first aspect, a kit for enriching, concentrating and / or detecting PCOS-related steroid hormones is provided.
[0067] The PCOS-related steroid hormones include one or more of progesterone, 17α-hydroxyprogesterone, 11-deoxycorticosterone, aldosterone, 11-deoxycortisol, cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstenedione, testosterone, 17α-hydroxypregnenolone, pregnenolone and dihydrotestosterone.
[0068] In an optional embodiment, the PCOS-related steroid hormones include progesterone, 17α-hydroxyprogesterone, 11-deoxycorticosterone, aldosterone, 11-deoxycortisol, cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstenedione, testosterone, 17α-hydroxypregnenolone, pregnenolone and dihydrotestosterone.
[0069] The kit for enriching, concentrating and / or detecting PCOS-related steroid hormones contains:
[0070] (I) Amphiphilic magnetic solid phase materials.
[0071] The amphiphilic magnetic solid phase material is a magnetic particle with a carbonaceous phase on the surface obtained by mixing magnetic particles SiO2@Fe3O4 with humic acid and then pyrolyzing at a temperature of 300~900°C for 0.5~1.5 h; the magnetic particles SiO2@Fe3O4 are nanoparticles with a core-shell structure of SiO2 coated with Fe3O4. The humic acid on the surface of the magnetic particles has a carbonaceous mesophase composed of a hydrophobic framework and abundant hydrophilic groups after pyrolysis. The temperature of the pyrolysis treatment can be, for example, but not limited to, 300, 400, 500, 600, 700, 800 or 900°C, and the time of the pyrolysis treatment can be, for example, but not limited to, 0.5, 1 or 1.5h.
[0072] In an optional embodiment, the temperature of the pyrolysis treatment is 600° C., and the time of the pyrolysis treatment is 1 h.
[0073] In an optional embodiment, the mass ratio of the humic acid to the SiO2@Fe3O4 magnetic particles is 0.05-0.5, for example, it can be but not limited to 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45 or 0.5, preferably 0.1.
[0074] In an optional embodiment, the particle size of the amphiphilic magnetic solid phase material is 1 to 50 μm, for example, but not limited to 1, 5, 10, 20, 30 or 50 μm.
[0075] In an optional embodiment, the preparation method includes dissolving humic acid in water in a reaction container, then adding a formulated amount of SiO2@Fe3O4 magnetic particles, stirring the suspension, and then removing water; subjecting the obtained solid to a pyrolysis treatment at a temperature of 300~900°C in a nitrogen flow for 0.5~1.5 h to convert the humic acid-modified SiO2@Fe3O4 into carbonaceous phase magnetic particles with a hydrophilic-lipophilic balance, and washing the magnetic particles with water until the washing wastewater is neutral.
[0076] In an optional embodiment, the mass ratio of the humic acid to the SiO2@Fe3O4 magnetic particles is 0.05-0.5, for example, it can be but not limited to 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45 or 0.5, preferably 0.1.
[0077] In an optional embodiment, the concentration of the humic acid aqueous solution is 1-5 g / L, preferably 2 g / L.
[0078] In an alternative embodiment, the water is removed using a rotary evaporator.
[0079] In an alternative embodiment, the pyrolysis process is carried out in an alumina combustion boat within a quartz tube.
[0080] The SiO2@Fe3O4 magnetic particles can be prepared by any optional and known method in the art, and the present invention is not limited thereto.
[0081] In an optional embodiment, the SiO2@Fe3O4 magnetic particles are prepared using a sol-gel method.
[0082] In an optional embodiment, the sol-gel method includes suspending Fe3O4 powder in purified water and ultrasonicating, then adding cetyltrimethylammonium bromide (CTAB) powder and triethanolamine (TEOA), and stirring the mixture at 70-90°C for 0.5-1.5 h. SiO2@Fe3O4 particles are recovered by filtration, washed and dried, and then calcined at 500-580°C for 6-8 h to obtain SiO2@Fe3O4 magnetic particles.
[0083] In an optional embodiment, the ultrasonic time is 20 to 40 min, preferably 30 min.
[0084] In an optional embodiment, the molar ratio of Fe3O4, cetyltrimethylammonium bromide and triethanolamine is (0.8~1.2):(0.8~1.2):(1.5~2), preferably 1:1:1.5.
[0085] In an optional embodiment, Fe3O4, cetyltrimethylammonium bromide and triethanolamine are continuously stirred at a temperature of, for example but not limited to, 70, 75, 80, 85 or 90°C, preferably 80°C.
[0086] In an optional embodiment, the continuous stirring time may be, for example but not limited to, 0.5, 1 or 1.5 h, preferably 1.5 h.
[0087] In an alternative embodiment, stirring is continued in a constant temperature water bath.
[0088] In an optional embodiment, ethanol is used to wash, filter and recover the SiO2@Fe3O4 particles.
[0089] In an optional embodiment, the drying comprises drying at 55-65° C. for 20-30 h. The drying temperature may be, for example, but not limited to, 55, 60 or 65° C.; the drying time may be, for example, but not limited to, 20, 22, 24, 26, 28 or 30 h.
[0090] In an optional embodiment, the drying comprises drying at 60° C. for 24 hours.
[0091] In an optional embodiment, the calcination temperature may be, for example but not limited to, 500, 510, 520, 530, 540, 550, 560, 570 or 580°C, preferably 540°C.
[0092] In an optional embodiment, the calcination time may be, for example but not limited to, 6, 6.5, 7, 7.5 or 8 h, preferably 7 h.
[0093] (II) Activation solution, equilibration solution, dissociation solution, first eluent, second eluent and elution solution:
[0094] The activation solution includes methanol;
[0095] The equilibrium solution includes an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-10%, and the proportion of methanol is not 0; the volume ratio of methanol to water can be, for example, but not limited to, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, preferably, the volume ratio of methanol to water is 5%.
[0096] The dissociation solution includes an ammonium acetate-acetic acid buffer solution with a pH range of 5 to 6, preferably 5.5.
[0097] The first eluent includes an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-30%, and the proportion of methanol is not 0; the volume ratio of methanol to water can be, for example, but not limited to, 1%, 5%, 10%, 15%, 20%, 25% or 30%, preferably, the volume ratio of methanol to water is 15%.
[0098] The second eluent includes one or more of n-hexane, isohexane and cyclohexane, preferably n-hexane.
[0099] The eluent includes one or more of methanol, acetonitrile and isopropanol solution.
[0100] In an optional embodiment, the kit further comprises: (III) one or more of a calibrator, a quality control material, an internal standard and a blank matrix.
[0101] In an optional embodiment, the blank matrix is a biological matrix, the biological matrix includes an aqueous solution of serum or serum albumin, and the biological matrix is pre-treated to remove endogenous steroid hormones. The removal refers to making the content of endogenous steroid hormones in serum below the detection threshold.
[0102] In an optional embodiment, the pre-treatment for removing endogenous steroid hormones includes using a macroporous adsorption resin to adsorb the endogenous steroid hormones in the biological matrix.
[0103] In an optional embodiment, the calibrator is prepared from the blank matrix.
[0104] In an optional embodiment, the quality control product is prepared from the blank matrix.
[0105] Using the above blank matrix to prepare calibration products and / or quality control products can simulate the real matrix environment, reduce the influence of matrix effects, and improve the accuracy of quantification.
[0106] In an optional embodiment, the macroporous adsorption resin is a non-polar macroporous adsorption resin or a medium-polar macroporous adsorption resin. A non-polar macroporous adsorption resin refers to a resin without any functional group and with a strong hydrophobicity on the pore surface, which is obtained by polymerization of monomers with very small dipole moments. A medium-polar macroporous adsorption resin refers to an adsorption resin containing an ester group, and the hydrophobic part and the hydrophilic part coexist on its surface.
[0107] In view of the problem that the operation of preparing blank serum by activated carbon adsorption is cumbersome and time-consuming, and the activated carbon is easy to remain in the matrix solution after adsorption and is extremely difficult to be completely separated, a high-molecular polymer adsorbent with large particles, stable structure and low price is preferably used, which does not need to adjust the pH of the biological matrix and can directly adsorb endogenous small molecules of the biological matrix. The whole operation process is simple and fast. After adsorption, the adsorbent can be completely separated from the biological matrix without having a significant impact on the original biological matrix. The prepared calibration product or quality control product can better simulate the biological matrix and improve the accuracy of the quantitative results.
[0108] In an optional embodiment, the pre-treatment for removing endogenous steroid hormones comprises:
[0109] (a) Activation: Take an appropriate amount of macroporous adsorption resin and place it in a container. After adding ethanol to soak it, separate the macroporous adsorption resin; then wash it with ethanol and purified water respectively to obtain the activated macroporous adsorption resin.
[0110] (b) Adsorption: Add the activated macroporous adsorption resin to the biological matrix for mixed adsorption, and collect the biological matrix by vacuum filtration. The low-speed mixed adsorption speed is preferably 50-200 rpm, and the mixed adsorption time is 0.5-2 hours, preferably 1 hour.
[0111] In an alternative embodiment, the serum albumin comprises bovine serum albumin (BSA).
[0112] In an optional embodiment, the kit further comprises: (IV) a mobile phase.
[0113] In an optional embodiment, the mobile phase includes mobile phase A and mobile phase B;
[0114] The mobile phase A is an aqueous solution of ammonium formate or an aqueous solution of ammonium acetate, and the mobile phase A contains no more than 0.001% v / v formic acid.
[0115] In an optional embodiment, the concentration of ammonium formate or ammonium acetate in mobile phase A is 2 mM.
[0116] In an optional embodiment, the mobile phase A contains 0.001% v / v formic acid.
[0117] In an optional embodiment, the mobile phase A is a 2 mM ammonium formate aqueous solution containing 0.001% v / v formic acid.
[0118] The mobile phase B is a methanol solution of ammonium formate or a methanol solution of ammonium acetate, and the mobile phase B contains no more than 0.001% v / v formic acid.
[0119] In an optional embodiment, the concentration of ammonium formate or ammonium acetate in mobile phase B is 2 mM.
[0120] In an optional embodiment, the mobile phase B contains 0.001% v / v formic acid.
[0121] In an optional embodiment, the mobile phase B is a 2 mM ammonium formate methanol solution containing 0.001% v / v formic acid.
[0122] In a second aspect, a sample pretreatment method is also provided, comprising using the amphiphilic magnetic solid phase material described in the first aspect, or the kit provided in the first aspect to enrich and / or concentrate the PCOS-related steroid hormones in the sample. The sample treated by the pretreatment method can be used to detect the PCOS-related steroid hormones therein by any method acceptable in the art.
[0123] The sample pretreatment method comprises mixing the amphiphilic magnetic solid phase material which has been subjected to activation treatment and equilibrium treatment in sequence with the sample system, so that the amphiphilic magnetic solid phase material adsorbs the PCOS-related steroid hormone in the sample, and then separating the amphiphilic magnetic solid phase material and mixing it with a first eluent, separating the amphiphilic magnetic solid phase material and then mixing it with a second eluent, eluting with an eluent and collecting the eluent, wherein the eluent contains the PCOS-related steroid hormone in the sample for subsequent detection; the activation treatment comprises mixing the activation solution with the amphiphilic magnetic solid phase material;
[0124] The activation treatment comprises mixing an activation solution with the amphiphilic magnetic solid phase material;
[0125] The balancing treatment comprises mixing the activated amphiphilic magnetic solid phase material with a balancing solution;
[0126] The sample system includes a sample, methanol and a dissociation solution.
[0127] In an optional embodiment, the sample system further includes an internal standard.
[0128] In an optional embodiment, the volume ratio of methanol to dissociation solution in the sample system is (2-4):8, preferably 3:8.
[0129] In an optional embodiment, the mass volume ratio of the amphiphilic magnetic solid phase material to the sample to be tested is 50:(100-500) mg / μL, preferably 50:200 mg / μL.
[0130] The activation solution, balancing solution, dissociation solution, first eluent, second eluent and elution solution in the sample pretreatment method are composed as follows:
[0131] The activation solution includes methanol;
[0132] The equilibrium solution includes an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-10%, and the proportion of methanol is not 0; the volume ratio of methanol to water can be, for example, but not limited to, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, preferably, the volume ratio of methanol to water is 5%.
[0133] The dissociation solution comprises an ammonium acetate-acetic acid buffer solution with a pH range of 5-6, preferably 5.5.
[0134] The first eluent includes an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-30%, and the proportion of methanol is not 0; the volume ratio of methanol to water can be, for example, but not limited to, 1%, 5%, 10%, 15%, 20%, 25% or 30%, preferably, the volume ratio of methanol to water is 15%.
[0135] The second eluent includes one or more of n-hexane, isohexane and cyclohexane, preferably n-hexane.
[0136] The eluent includes one or more of methanol, acetonitrile and isopropanol solution.
[0137] In a third aspect, a method for detecting PCOS-related steroid hormones is also provided, comprising enriching and / or concentrating the PCOS-related steroid hormones in the sample using the amphiphilic magnetic solid phase material of the first aspect, and then analyzing the PCOS-related steroid hormones in the sample using liquid chromatography tandem mass spectrometry;
[0138] In an optional embodiment, the enrichment and / or concentration of PCOS-related steroid hormones in the sample using the amphiphilic magnetic solid phase material of the first aspect includes enrichment and / or concentration of PCOS-related steroid hormones in the sample using the sample pretreatment method of the second aspect.
[0139] Liquid chromatography conditions included:
[0140] The chromatographic column adopts a C18 chromatographic column, and the C18 chromatographic column includes any C18 chromatographic column known in the art, and also includes a chromatographic column with further added modification groups based on the C18 chromatographic column, such as a T3 chromatographic column.
[0141] In an optional embodiment, the chromatographic column uses an ACQUITY UPLC HSS T3 chromatographic column, and the specifications are preferably 50×2.1 mm 1.8 μm.
[0142] The mobile phase system includes mobile phase A and mobile phase B;
[0143] The mobile phase A is an aqueous solution of ammonium formate or an aqueous solution of ammonium acetate, and the mobile phase A contains no more than 0.001% v / v formic acid.
[0144] In an optional embodiment, the concentration of ammonium formate or ammonium acetate in mobile phase A is 2 mM.
[0145] In an optional embodiment, the mobile phase A contains 0.001% v / v formic acid.
[0146] In an optional embodiment, the mobile phase A is a 2 mM ammonium formate aqueous solution containing 0.001% v / v formic acid.
[0147] The mobile phase B is a methanol solution of ammonium formate or a methanol solution of ammonium acetate, and the mobile phase B contains no more than 0.001% v / v formic acid.
[0148] In an optional embodiment, the concentration of ammonium formate or ammonium acetate in mobile phase B is 2 mM.
[0149] In an optional embodiment, the mobile phase B contains 0.001% v / v formic acid.
[0150] In an optional embodiment, the mobile phase B is a 2 mM ammonium formate methanol solution containing 0.001% v / v formic acid.
[0151] According to the gradient elution, the elution program is:
[0152] From 0 to 6 min, the volume ratio of the mobile phase A to the mobile phase B changed from 55:45 to 35:65;
[0153] At 6-6.7 min, the volume ratio of the mobile phase A to the mobile phase B was changed from 35:65 to 0:100;
[0154] At 6.7-7.7 min, the volume ratio of the mobile phase A to the mobile phase B was maintained at 0:100;
[0155] At 7.7-7.9 min, the volume ratio of the mobile phase A to the mobile phase B changed from 0:100 to 55:45;
[0156] At 7.9-8.5 min, the volume ratio of the mobile phase A to the mobile phase B was maintained at 55:45.
[0157] In an optional embodiment, the mobile phase flow rate is 0.4 mL / min.
[0158] In an optional embodiment, the column temperature of the chromatographic column is 40°C.
[0159] In an optional embodiment, the injection volume is 20 μL.
[0160] In an optional embodiment, the mass spectrometry conditions include: ESI+ and ESI- ion ionization positive and negative simultaneous monitoring mode, ion source temperature 120~150℃, capillary voltage: 1.5~2.5 kV, desolvation gas temperature: 400~600℃, desolvation gas: 800~1000 L / Hr, cone gas: 0~150 L / Hr, and scanning using multiple reaction monitoring.
[0161] In an optional embodiment, the mass spectrometry conditions include: ESI+ and ESI- ion ionization positive and negative simultaneous monitoring mode, ion source temperature of 150°C, capillary voltage: 2 kV, desolvation gas temperature: 500°C, desolvation gas: 1000 L / Hr, cone gas: 150L / Hr, and scanning using multiple reaction monitoring.
[0162] In an optional embodiment, the mass spectrometry parameters are as follows:
[0163] Table 1
[0164]
[0165] Where IS stands for internal standard.
[0166] In an optional embodiment, the content of the PCOS-related steroid hormone is analyzed and calculated by the internal standard method.
[0167] In an optional embodiment, the method for detecting PCOS-related steroid hormones also includes detecting a calibrator, drawing a calibration curve based on the concentration of PCOS-related steroid hormones in the calibrator and the detection results of liquid chromatography tandem mass spectrometry, and then converting the concentration or content of each steroid hormone in the sample to be tested according to the detection results of liquid chromatography tandem mass spectrometry of the sample to be tested.
[0168] The PCOS-related steroid hormones in the second and third aspects above include one or more of progesterone, 17α-hydroxyprogesterone, 11-deoxycorticosterone, aldosterone, 11-deoxycortisol, cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstenedione, testosterone, 17α-hydroxypregnenolone, pregnenolone and dihydrotestosterone; optionally include progesterone, 17α-hydroxyprogesterone, 11-deoxycorticosterone, aldosterone, 11-deoxycortisol, cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstenedione, testosterone, 17α-hydroxypregnenolone, pregnenolone and dihydrotestosterone.
[0169] The samples in the second and third aspects above include, but are not limited to, samples of blood, body fluids, urine, saliva, tissues or cells separated from an organism, and the samples may also optionally include artificially prepared samples containing known amounts of PCOS-related steroid hormones for constructing a standard curve or for verifying the test results.
[0170] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0171] Example 1
[0172] This embodiment provides a steroid hormone detection kit, comprising:
[0173] Amphiphilic (hydrophilic and lipophilic) magnetic solid phase materials; calibrators and quality controls containing different concentrations of steroid hormones prepared in biological matrices; internal standard working solutions; and solutions used in sample pretreatment as follows:
[0174] Activation liquid: pure methanol;
[0175] Balance solution: 5% v / v methanol-water solution;
[0176] Dissociation solution: ammonium acetate-acetic acid buffer solution with a pH of 5.5;
[0177] Eluent 1 (elution I): 15% v / v methanol-water solution;
[0178] Eluent 2 (elution II): n-hexane;
[0179] Eluent: pure acetonitrile.
[0180] 1 The amphiphilic (hydrophilic and lipophilic) magnetic solid phase material is prepared by the following steps:
[0181] (1) Preparation of magnetic particles by sol-gel method: 1 g of Fe3O4 was suspended in 90 ml of water and ultrasonicated for 30 min. Subsequently, 1.7 g of hexadecyltrimethylammonium bromide (CTAB) and 1 g of triethanolamine (TEOA) were added, and the mixture was stirred continuously in a constant temperature water bath at 80 °C for 1 h using a mechanical stirrer. The SiO2@Fe3O4 was recovered by filtration, washed with 50 mL of ethanol, taken out and dried in an oven at 60 °C for 24 h, and then calcined at 540 °C for 7 h to obtain SiO2@Fe3O4 magnetic particles.
[0182] (2) Preparation of magnetic solid phase extraction material by one-pot method: 200 mg of humic acid was dissolved in 100 ml of distilled water in a round-bottom flask, and then 2 g of air-calcined SiO2@Fe3O4 magnetic particles were added and the suspension was stirred for 2 minutes. The water was removed by rotary evaporator, and the obtained solid was pyrolyzed in an alumina combustion boat in a quartz tube at 600°C in a N2 gas flow for 1 hour to convert it into a hydrophilic-lipophilic balanced carbonaceous phase magnetic particles. The magnetic particles were washed with a large amount of distilled water in a filter flask until the eluent was neutral.
[0183] 2 Blank matrix was prepared by the following steps:
[0184] 500g of macroporous adsorption resin was placed in a beaker, and ethanol was added to soak it. The solvent was then filtered using a Buchner funnel and medical absorbent cotton gauze. The activated macroporous adsorption resin was then washed twice with ethanol and purified water. 300g of the activated macroporous adsorption resin was added to 900mL of bovine serum, and an electric stirrer was used to mix and adsorb for 1h at a speed of 75rpm, and a blank calf serum matrix was obtained by vacuum filtration.
[0185] 3 Preparation of Calibrators and Quality Controls
[0186] 3.1 The preparation scheme of SW6 intermediate solution is shown in the following table:
[0187] Table 2 Preparation of SW6 intermediate solution
[0188]
[0189] As shown in Table 2, take a 250 mL volumetric flask and add the primary stock solution of each analyte according to the above table. After vortex mixing for 5 minutes, add 50% v / v methanol-water solution to the scale line, and mix upside down for 2 minutes to obtain the SW6 intermediate solution of the highest point of the calibration product.
[0190] 3.2 The preparation scheme of the calibration material is shown in the following table:
[0191] Table 3 Preparation scheme of SW1~6 intermediate solution
[0192]
[0193] The concentrations shown above are based on progesterone concentrations, and the remaining concentrations are diluted at the same multiple. According to the scheme shown in the table above, dilute the SW6 intermediate solution obtained in 3.1 to obtain the SW1-SW5 intermediate solutions. Then take 1 volume of the intermediate solution, add 9 volumes of the blank matrix liquid obtained after the treatment in step 2, mix thoroughly for 30 minutes, and prepare 6 calibration products J1-J6 with different concentrations. The concentrations of each analyte in the calibration product are shown in the following table:
[0194] Table 4 Concentration of analytes in calibrators
[0195]
[0196] 3.3 The preparation scheme of quality control products is shown in the following table:
[0197] Table 5 Preparation of quality control products
[0198]
[0199] The concentrations shown above are based on progesterone concentrations, and the remaining concentrations are diluted at the same multiple. According to the scheme shown in the table above, dilute the SW6 intermediate solution obtained in 3.1 to obtain QCL and QCH intermediate solutions. Then take 1 volume of the intermediate solution, add 9 volumes of the blank matrix liquid obtained after treatment in step 2, mix thoroughly for 30 minutes, and prepare 2 quality control products QCL and QCH with different concentrations. The concentrations of each analyte in the quality control product are shown in the following table:
[0200] Table 6 Concentration of analytes in quality control products
[0201]
[0202] 4. For the preparation of internal standard working solution, please refer to the following table:
[0203] Table 7 Preparation of internal standard working solution
[0204]
[0205] Use methanol as the diluent and dilute the internal standard stock solution into the internal standard working solution of the corresponding concentration according to the above table.
[0206] Example 2
[0207] This example provides a method for detecting steroid hormones, using the kit provided in Example 1 to detect steroid hormones.
[0208] 1. Sample pretreatment:
[0209] 1.1 Magnetic solid phase extraction pre-treatment operation process:
[0210] Take a deep-well plate for the pretreatment process, and add the solvents used in the entire treatment process according to the layout of solvents and samples shown in Table 8. Add 50 mg of magnetic adsorption material, 200 μL of calibrator, quality control product or sample to be tested (blood or serum) to position 3, and then add 50 μL of internal standard solution to each well in turn, vortex mix for 3 minutes; then add 150 μL of methanol solution and 400 μL of dissociation solution.
[0211] As can be seen from the layout diagram, samples can be added at positions 3 and 9, and each board can pre-process up to 16 samples.
[0212] Table 8
[0213]
[0214] Then use the automated sample processor to perform magnetic bead activation, magnetic bead balance, sample dissociation and adsorption, first elution, second elution and elution in sequence according to the mixing method, mixing time and adsorption time in the table below. The specific steps are as follows:
[0215] Step (1) Take a deep well plate, add the sample to be tested and the internal standard solution to position 3, and mix well; then add methanol and dissociation solution;
[0216] Step (2) Activation: Add magnetic beads to position 1 and activate the magnetic beads using methanol;
[0217] Step (3) balancing: using an automated sample processor to move the magnetic beads obtained after the treatment in step (2) into position 2, and balancing the magnetic beads using a methanol-water solution;
[0218] Step (4) extraction: use an automated sample processor to transfer the magnetic beads obtained after processing in step (3) into position 3 and mix well;
[0219] Step (5) Wash 1: Use an automated sample processor to transfer the magnetic beads into the wash solution 1 at position 4 and mix well;
[0220] Step (6) Wash 2: Use an automated sample processor to transfer the magnetic beads after the first wash to the wash solution 2 at position 5 and mix well;
[0221] Step (7) Elution: Use an automated sample processor to transfer the magnetic beads into the elution solution, mix well, then discard the magnetic beads, dilute the elution solution online and transfer it to the sample plate, and prepare for testing on the machine;
[0222] Table 9
[0223]
[0224] 2. Sample testing:
[0225] 2.1 Chromatographic conditions:
[0226] Liquid chromatography-tandem mass spectrometer: Waters Xevo TQS;
[0227] The chromatographic column used was an ACQUITY UPLC HSS T3 column with specifications of 50 × 2.1 mm 1.8 μm;
[0228] Mobile phase A was 100,000 parts formic acid (0.001% v / v)-2 mM ammonium formate-water;
[0229] Mobile phase B (aqueous phase) was 100,000 parts formic acid (0.001% v / v)-2 mM ammonium formate-methanol;
[0230] The column temperature is 40.0℃ and the injection volume is 20μL. The liquid phase elution program is shown in the following table:
[0231] Table 10 Elution program
[0232]
[0233] 2.2 Mass spectrometry conditions
[0234] Electrospray ionization (ESI) source, ESI+ and ESI- ion ionization positive and negative simultaneous monitoring mode (Note: DHEAS is ESI- mode). Ion source temperature 150℃, capillary voltage Capillary: 2 kV, desolvation temperature Desolvation Temp: 500℃, desolvation gas Desolvation: 1000 L / Hr, cone gas Cone: 150 L / Hr. Multiple reaction monitoring (MRM) was used for scanning. Mass spectrometry ion pair parameters and other information are shown in the following table:
[0235] Table 11 Mass spectrometry parameters
[0236]
[0237] Example 3
[0238] Performance verification of the steroid detection method provided in Example 2:
[0239] 1. Linear range:
[0240] According to the preparation method of the calibrator in step 3.2 of Example 1, the treated calibrator was tested on the machine. The concentration of the calibrator is shown in Table 4, and the test results are shown in Figure 1 to Figure 26 As shown, all chromatographic peaks have good peak shapes and are baseline separated from other analytes, with good linearity and a correlation coefficient above 0.99. All 13 analytes also have a recovery rate between 90% and 110%, meeting the quantitative requirements.
[0241] 2. Precision
[0242] The detection method of Example 2 was used to perform three parallel experiments on the quality control product for five consecutive days. The average of the three experimental test values was taken as the measured value. The intra-batch and inter-batch coefficients of variation and the total coefficient of variation of the test results were investigated. The results are as follows:
[0243] Table 12
[0244]
[0245] 3. Accuracy:
[0246] Different concentrations of steroid hormone standards were added to blank human serum matrix to prepare samples at low, medium and high concentration levels. The concentrations are shown in the table below. Spiked samples were processed in parallel 3 times and the relative deviation of the spiked sample results was calculated. The results are shown in the table:
[0247] Table 13
[0248]
[0249] Example 4
[0250] Optimization of pyrolysis temperature of amphiphilic magnetic solid phase extraction materials
[0251] In this embodiment, the silica-coated magnetic particles SiO2@Fe3O4 were prepared by the sol-gel method according to step 1 of embodiment 1. Then, 200 mg of humic acid was dissolved in 100 ml of distilled water in a round-bottom flask, and then 2 g of SiO2@Fe3O4 magnetic particles calcined in air were added, and the suspension was stirred for 2 minutes. The water was removed by a rotary evaporator, and the obtained solid was pyrolyzed in an alumina combustion boat in a quartz tube at 300°C, 600°C, and 900°C in a N2 gas flow for 1 hour to convert it into a hydrophilic-lipophilic balanced carbonaceous phase magnetic particles. The magnetic particles were washed with a large amount of distilled water in a filter flask until the eluent was neutral. Adsorbent material 1 (300°C pyrolysis), adsorbent material 2 (600°C pyrolysis), and adsorbent material 3 (900°C pyrolysis) were obtained.
[0252] The QCH intermediate solution in Example 1 was diluted 10 times with pure water, and the above three adsorbent materials were used to extract and detect according to the method of Example 2. The peak area was compared with the analytes obtained by direct injection detection, and the extraction recovery rate of each analyte was calculated. The results are shown in the following table:
[0253] Table 14
[0254]
[0255] As shown in the table above, different pyrolysis temperatures have a great influence on the absolute recovery rate during the extraction process. It can be seen that controlling the pyrolysis temperature during the preparation process can enable the magnetic solid phase extraction filler to better combine with steroid hormones, thereby improving the extraction efficiency and quantitative accuracy, and meeting the clinical demand for high-accuracy detection of steroid hormones. The optimal pyrolysis temperature is 600°C.
[0256] Example 5
[0257] Mobile phase optimization:
[0258] In the actual sample testing, we found that there were different degrees of interference between the 17-hydroxypregnenolone internal standard and the dihydrotestosterone analyte. It was difficult to completely separate the impurity peaks using a conventional mobile phase containing 0.1% v / v formic acid. The mobile phase formulas used and the comparison results are shown in the following table. The other test conditions are the same as in Example 2:
[0259] Table 15
[0260]
[0261] The results are shown in Table 15. Using the first group of mobile phases, the dihydrotestosterone chromatogram is as follows: Fig. 27 As shown in Figure 1, it can be seen that there is an interference peak for dihydrotestosterone; the chromatogram of 17-hydroxypregnenolone-IS is shown in Figure 1. Fig.28 As shown, it can be seen that there is a large interference peak near 17-hydroxypregnenolone-IS. Fig. 27 and Fig.28 This indicates that the first group of mobile phases affects the quantification of PCOS-related steroid hormones. Using the second group of mobile phases, the chromatogram of dihydrotestosterone is as follows: Fig.29 As shown in Figure 2, it can be seen that the interference peak overlaps with dihydrotestosterone; the chromatogram of 17-hydroxypregnenolone-IS is shown in Figure 2. Fig.30 As shown, it can be seen that 17-hydroxypregnenolone-IS has a large interference peak. Fig.29 and Fig.30 This indicates that the second group of mobile phases affects the quantification of PCOS-related steroid hormones. Using the third group of mobile phases, the chromatograms of dihydrotestosterone and 17-hydroxypregnenolone-IS are as follows: Fig.31 and Fig.32 As shown, it can be seen that the interference peaks and the target analytes are completely separated. Fig.31 and Fig.32 This indicates that the third group of mobile phases has the best separation effect.
[0262] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A kit for enriching, concentrating and / or detecting PCOS-related steroid hormones, characterized in that: The method comprises an amphiphilic magnetic solid phase material, an activation solution, a balancing solution, a dissociation solution, a first eluent, a second eluent and an elution solution; The amphiphilic magnetic solid phase material is prepared according to the following method: humic acid is dissolved in water in a reaction container, and then a formula amount of SiO2@Fe3O4 magnetic particles is added, and the suspension is stirred, and then the water is removed; the obtained solid is subjected to pyrolysis treatment at a temperature of 300-900° C. in a nitrogen flow for 0.5-1.5 h, and after the reaction is completed, it is washed with water until the washing waste liquid is neutral, and the obtained magnetic particles have a carbonaceous phase on the surface; The magnetic particles SiO2@Fe3O4 are nanoparticles with a core-shell structure in which SiO2 covers Fe3O4. The activation solution includes methanol; The equilibrium solution comprises an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-10%, and the proportion of methanol is not 0; The dissociation solution includes an ammonium acetate-acetic acid buffer solution with a pH range of 5 to 6; The first eluent comprises an aqueous solution of methanol, wherein the volume ratio of methanol to water is 0-30%, and the proportion of methanol is not 0; The second eluent comprises one or more of n-hexane, isohexane and cyclohexane; The eluent includes one or more of methanol, acetonitrile and isopropanol solution; The PCOS-related steroid hormones include one or more of progesterone, 17α-hydroxyprogesterone, 11-deoxycorticosterone, aldosterone, 11-deoxycortisol, cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstenedione, testosterone, 17α-hydroxypregnenolone, pregnenolone and dihydrotestosterone.
2. The kit according to claim 1, characterized in that The temperature of the pyrolysis treatment is 600°C, and the time of the pyrolysis treatment is 1 h; And / or, the mass ratio of the humic acid to the SiO2@Fe3O4 magnetic particles is 0.05-0.
5.
3. The kit according to claim 1 or 2, characterized in that Also includes one or more of calibrators, quality control products, internal standards, blank matrix and mobile phase; The blank matrix is a biological matrix, the biological matrix includes an aqueous solution of serum or serum albumin, and the biological matrix is pre-treated to remove endogenous steroid hormones; The calibrator and / or the quality control product are prepared from the blank matrix; The mobile phase includes mobile phase A and mobile phase B; The mobile phase A is an aqueous solution of ammonium formate or ammonium acetate, and the mobile phase A contains no more than 0.001% v / v formic acid; The mobile phase B is a methanol solution of ammonium formate or a methanol solution of ammonium acetate, and the mobile phase B contains no more than 0.001% v / v formic acid.
4. The kit according to claim 3, characterized in that The pretreatment for removing endogenous steroid hormones includes using macroporous adsorption resin to remove endogenous steroid hormones in the biological matrix.
5. A sample pre-processing method, characterized in that: The method comprises using the amphiphilic magnetic solid phase material described in any one of claims 1 to 4, or using the kit for enriching, concentrating and / or detecting PCOS-related steroid hormones described in any one of claims 1 to 4 to enrich and / or concentrate the PCOS-related steroid hormones in the sample; The sample pretreatment method comprises mixing the amphiphilic magnetic solid phase material that has been subjected to activation treatment and equilibrium treatment in sequence with a sample system, so that the amphiphilic magnetic solid phase material adsorbs PCOS-related steroid hormones in the sample, and then separating the amphiphilic magnetic solid phase material and mixing it with a first eluent, separating the amphiphilic magnetic solid phase material and then mixing it with a second eluent, eluting with an eluent and collecting the eluent, wherein the eluent contains the PCOS-related steroid hormones in the sample for subsequent detection; The activation treatment comprises mixing an activation solution with the amphiphilic magnetic solid phase material; The balancing treatment comprises mixing the activated amphiphilic magnetic solid phase material with a balancing solution; The sample system includes a sample, methanol and a dissociation solution; The activation solution is the activation solution described in claim 1; the balancing solution is the balancing solution described in claim 1; the dissociation solution is the dissociation solution described in claim 1; the first eluent is the first eluent described in claim 1; the second eluent is the second eluent described in claim 1; and the elution solution is the elution solution described in claim 1.
6. A method for detecting PCOS-related steroid hormones, characterized in that: The method comprises using the amphiphilic magnetic solid phase material described in claim 1 to enrich and / or concentrate PCOS-related steroid hormones in a sample, and then analyzing the PCOS-related steroid hormones in the sample by liquid chromatography tandem mass spectrometry; Liquid chromatography conditions included: The chromatographic column used is C18 column; The mobile phase system includes mobile phase A and mobile phase B; The mobile phase A is an aqueous solution of ammonium formate or an aqueous solution of ammonium acetate, and the mobile phase A contains no more than 0.001% v / v formic acid; the mobile phase B is a methanol solution of ammonium formate or a methanol solution of ammonium acetate, and the mobile phase B contains no more than 0.001% v / v formic acid.
7. The detection method according to claim 6, characterized in that: The sample pretreatment is performed using the sample pretreatment method according to claim 5.
8. The detection method according to claim 6, characterized in that: Liquid chromatography was performed according to gradient elution, and the elution procedure was: From 0 to 6 min, the volume ratio of the mobile phase A to the mobile phase B changed from 55:45 to 35:65; At 6-6.7 min, the volume ratio of the mobile phase A to the mobile phase B was changed from 35:65 to 0:100; At 6.7-7.7 min, the volume ratio of the mobile phase A to the mobile phase B was maintained at 0:100; At 7.7-7.9 min, the volume ratio of the mobile phase A to the mobile phase B changed from 0:100 to 55:45; At 7.9-8.5 min, the volume ratio of the mobile phase A to the mobile phase B was maintained at 55:
45.
9. The detection method according to claim 6, characterized in that The mass spectrometry conditions included: ESI+ and ESI- ion ionization positive and negative simultaneous monitoring mode, ion source temperature 120~150℃, capillary voltage: 1.5~2.5 kV, desolvation temperature: 400~600℃, desolvation gas: 800~1000 L / Hr, cone gas: 0~150 L / Hr, and scanning with multiple reaction monitoring.
